AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Trinity Biotech's CGM Sensor Receives Positive Clinical Trial Results, Poised for Commercialization
ByAinvest
Friday, Aug 15, 2025 11:12 am ET1min read
Trinity Biotech has announced positive clinical trial results for its next-generation continuous glucose monitoring (CGM) technology, CGM+. The redesigned sensor delivers accurate glucose readings for 15 days without finger-stick calibration and reduces disposable components, lowering the cost of care. The innovative approach is expected to enhance accessibility and adoption of CGM technology, addressing the high cost of existing devices. The global CGM market is projected to grow from $13 billion in 2025 to $28 billion by 2030, driven by rising diabetes prevalence and demand for real-time health data.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet